ArticlePloS one2017
Medication eluting devices for the field of OBGYN (MEDOBGYN): 3D printed biodegradable hormone eluting constructs, a proof of concept study.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- A process-driven approach for manufacturing personalized intravaginal rings using droplet deposition modeling.International journal of pharmaceutics · 2026Article
- Oxidation-degradable resins for 3D-printing of cell-responsive biomaterials.Advanced functional materials · 2025Article
- Applications and challenges of 3D printing in female reproductive system research.3D printing in medicine · 2025Article
- Article
- Point-of-care additive manufacturing: state of the art and adoption in Spanish hospitals during pre to post COVID-19 era.3D printing in medicine · 2024Article
- Personalization of Intravaginal rings by droplet deposition modeling based 3D printing technology.International journal of pharmaceutics · 2024Article
- Customizable Self-Microemulsifying Rectal Suppositories by Semisolid Extrusion 3D Printing.Pharmaceutics · 2024Article
- A Novel Intrauterine Device for the Spatio-Temporal Release of Norethindrone Acetate as a Counter-Estrogenic Intervention in the Genitourinary Syndrome of Menopause.Pharmaceutics · 2024Article
- Potential Applications and Additive Manufacturing Technology-Based Considerations of Mesoporous Silica: A Review.AAPS PharmSciTech · 2023Review
- Additive manufacturing and three-dimensional printing in obstetrics and gynecology: a comprehensive review.Archives of gynecology and obstetrics · 2023Review
- Rapid Prototyping Technologies: 3D Printing Applied in Medicine.Pharmaceutics · 2023Review
- Release Kinetics of Metronidazole from 3D Printed Silicone Scaffolds for Sustained Application to the Female Reproductive Tract.Biomedical engineering advances · 2023Article
- Review
- Additive manufacturing of sustainable biomaterials for biomedical applications.Asian journal of pharmaceutical sciences · 2023Review
- Individualized medicine using 3D printing technology in gynecology: a scoping review.3D printing in medicine · 2023Article
- Enhancing antioxidant delivery through 3D printing: a pathway to advanced therapeutic strategies.Frontiers in bioengineering and biotechnology · 2023Review
- Investigation of the Drug Carrier Properties of Insoluble Cyclodextrin Polymer Microspheres.Biomolecules · 2022Article
- The Evolution of the 3D-Printed Drug Delivery Systems: A Review.Pharmaceutics · 2022Review
- Additive Manufacturing Strategies for Personalized Drug Delivery Systems and Medical Devices: Fused Filament Fabrication and Semi Solid Extrusion.Molecules (Basel, Switzerland) · 2022Review
- Recent progress in advanced biomaterials for long-acting reversible contraception.Journal of nanobiotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3D printing has the potential to deliver personalized implants and devices for obstetric and gynecologic applications. The aim of this study is to engineer customizable and biodegradable 3D printed implant materials that can elute estrogen and/or progesterone. All 3D constructs were printed using polycaprolactone (PCL) biodegradable polymer laden with estrogen or progesterone and were subjected to hormone-release profile studies using ELISA kits. Material thermal properties were tested using thermogravimetric analysis and differential scanning calorimetry. The 3D printed constructs showed extended hormonal release over a one week period. Cytocompatibility and bioactivity were assessed using a luciferase assay. The hormone-laden 3D printed constructs demonstrated an increase in luciferase activity and without any deleterious effects. Thermal properties of the PCL and hormones showed degradation temperatures above that of the temperature used in the additive manufacturing process-suggesting that 3D printing can be achieved below the degradation temperatures of the hormones. Sample constructs in the shape of surgical meshes, subdermal rods, intrauterine devices and pessaries were designed and printed. 3D printing of estrogen and progesterone-eluting constructs was feasible in this proof of concept study. These custom designs have the potential to act as a form of personalized medicine for drug delivery and optimized fit based on patient-specific anatomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.